Skip to main content

Table 2 Multivariable Cox regression analysis for distant disease-free survival

From: Prognostic impact of CD4-positive T cell subsets in early breast cancer: a study based on the FinHer trial patient population

Covariable Distant disease-free survivalHR (95% CI) P
CXCL13 expression
 ≤ Median ref.  
 > Median 0.44 (0.29–0.67) < 0.001
FOXP3 expression
  ≤ Median ref. 0.400
 > Median 1.20 (0.78–1.84)  
CD4 expression
  ≤ Median ref. 0.396
 > Median 1.89 (0.80–1.78)  
Age at study entry
 ≤50 years Ref. 0.516
 >50 years 0.88 (0.62–1.27)  
Tumor size   0.105
 pT1 Ref.  
 pT2 1.22 (0.82–1.81) 0.330
 pT3 1.89 (1.05–3.40) 0.034
Axillary nodal status   < 0.001
 pN0 Ref.  
 pN1 4.51 (1.94–10.52) < 0.001
 pN2 14.27 (4.78–42.71) < 0.001
Histological grade   0.229
 I Ref.  
 II 2.06 (0.86–4.95) 0.105
 III 2.22 (0.88–5.52) 0.088
Molecular subtype   < 0.001
 Luminal A-like Ref.  
 Luminal B-like 1.79 (1.01–3.14) 0.045
 Triple-negative 4.18 (2.30–7.59) < 0.001
 HER2-positive 2.71 (1.56–4.68) < 0.001
  1. Abbreviations: CD4 cluster of differentiation 4, CI confidence interval, CXCL13 C-X-C motif chemokine ligand 13, FOXP3 forkhead box P3, HER2 human epidermal growth factor receptor 2, HR hazard ratio
\